Celastrol targets adenylyl cyclase-associated protein 1 to reduce macrophages-mediated inflammation and ameliorates high fat diet-induced metabolic syndrome in mice.
10.1016/j.apsb.2020.12.008
- Author:
Yuyu ZHU
1
;
Ning WAN
2
;
Xinni SHAN
1
;
Guoliang DENG
1
;
Qiang XU
1
;
Hui YE
2
;
Yang SUN
1
Author Information
1. State Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Sciences, Nanjing University, Nanjing 210023, China.
2. Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
- Publication Type:Journal Article
- Keywords:
CAP1;
Celastrol;
Inflammation;
Metabolic syndrome;
Resistin
- From:
Acta Pharmaceutica Sinica B
2021;11(5):1200-1212
- CountryChina
- Language:English
-
Abstract:
Metabolic syndrome is a clustering of metabolic disorder with unclear molecular mechanism. Increasing studies have found that the pathogenesis and progression of metabolic syndrome are closely related to inflammation. Here, we report celastrol, a traditional Chinese medicine, can improve high fat diet-induced metabolic syndrome through suppressing resistin-induced inflammation. Mechanistically, celastrol binds to adenylyl cyclase associated protein 1 (CAP1) and inhibits the interaction between CAP1 and resistin, which restrains the cyclic adenylate monophosphate (cAMP)-protein kinase A (PKA)-nuclear factor kappa-B (NF-
